Molecular genetic study comparing foilicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant

Faculté de Médecine, Institut National de la Santé et de la Recherche Médicale (U555), 13385 Marseille Cedex 5, France.
Human Pathlogy (Impact Factor: 2.81). 08/2006; 37(7):824-30. DOI: 10.1016/j.humpath.2006.01.030
Source: PubMed

ABSTRACT Although the follicular variant of papillary thyroid carcinoma (FVPTC) has been classified as a papillary cancer based on nuclear features, its follicular growth pattern and potential for hematogenous spread are more characteristic of follicular carcinoma. To gain insight into the biologic nature of FVPTC, we compared genetic alterations characteristic of papillary and follicular thyroid carcinomas in 24 FVPTCs and 26 classic PTC (CPTCs). In FVPTCs, we observed ras mutation in 6 of 24 cases (25%), BRAF mutation in 1 of 13 cases (7.6%), and ret rearrangement in 5 of 12 cases (41.7%). In CPTCs, we found ras mutation in no case, BRAF mutation in 3 of 10 cases (30%), and ret rearrangement in 5 of 11 cases (45%). One FVPTC exhibited simultaneous ras mutation and ret/PTC1 rearrangement, and one CPTC harbored simultaneous BRAF mutation and ret/PTC3 rearrangement. Based on these findings, we concluded that ras mutation correlates with follicular differentiation of thyroid tumors whereas ret activation is associated with papillary nuclei but not with papillary architecture. ret activation is not exclusive of ras or BRAF mutation, whereas ras and BRAF mutations are mutually exclusive. The implications of these results for follicular and papillary carcinogenesis are discussed.


Available from: Vasily V Vasko, Sep 24, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The macrofollicular variant of papillary thyroid carcinoma is a rare subtype of the follicular variant of papillary thyroid carcinoma and is usually characterized by an indolent clinical course. The tumors are prone to be misdiagnosed as benign due to their macrofollicular architecture and bland cytologic features. We report a rare case of the macrofollicular variant of papillary thyroid carcinoma with extensive lymph node metastases. The patient was a 48-year-old female with a right thyroid nodule and multiple enlarged lymph nodes in the right neck. It was not possible to make a definitive diagnosis of malignancy on fine-needle aspiration cytology and intraoperative frozen section. She underwent total thyroidectomy with right modified radical neck dissection. The surgical specimen showed a 2.5 × 1.5 × 10 cm, well-circumscribed macrofollicular variant of papillary thyroid carcinoma in the right lobe and multiple central and right lateral neck lymph node metastases. Molecular testing for BRAF, NRAS, HRAS, and KRAS was all negative. We then reviewed the demographic and clinicopathologic characteristics of 71 patients with the macrofollicular variant of papillary thyroid carcinoma. The cytologic or histopathologic diagnosis of macrofollicular variant of papillary thyroid carcinoma can be difficult. Extensive lymph node metastases caused by the macrofollicular variant of papillary thyroid carcinoma may occur even in the absence of capsular or lymphovascular invasion. This review will help to better understand the nature of the macrofollicular variant of papillary thyroid carcinoma.
    Endocrine Pathology 03/2014; 25(3). DOI:10.1007/s12022-014-9306-y · 1.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. RET/PTC rearrangement, RAS and BRAF mutations are considered to be mutually exclusive in papillary thyroid carcinoma (PTC). However, concomitant mutations of RET/PTC, RAS or BRAF have been reported recently, but its significance for tumor progression and survival remains unclear. We sought to examine the prognostic value of concomitant mutations in PTC. Methods. We investigated 88 PTC for concomitant mutations. Mutation in BRAF exon 15, KRAS, NRAS, and HRAS were studied by PCR-sequencing of tumor DNA; RET/PTC rearrangement was determined by RT-PCR-sequencing of tumor cDNA. Results. BRAFV600E was detected in 39 of 82 classic PTC (CPTC) and in all three tall cell variants (49%, 42/85). KRAS mutation (p.Q61R and p.S65N) was detected in 2 CPTC (2%, 2/88) and NRASQ61R in one CPTC and 2 follicular variant PTC (FVPTC) (3%, 3/88). KRASS65N was identified for the first time in thyroid cancer and could activate MAPK. RET/PTC-1 was detected in 9 CPTC, 1 tall cell variant, and 2 FVPTC. Concomitant BRAFV600E and KRAS, or BRAFV600E and RET/PTC-1 mutations were found in 2 CPTC, and 6 CPTC and one tall cell variant, respectively. In total, 11 concomitant mutations were found in 88 PTC samples (13%) and most of them were in advanced disease stage (8/11, 73%, P<0.01). Conclusions. Our data show that concomitant mutations are frequent event in advanced PTC and associated with poor prognosis. The concomitant mutations may represent intra-tumor heterogeneity and could exert a gene dosage effect to promote disease progression. KRASS65N can constitutively activate MAPK pathway.
    Thyroid: official journal of the American Thyroid Association 05/2014; DOI:10.1089/thy.2013.0610 · 3.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Molecular testing for oncogenic gene alterations provides clinically actionable information essential for the optimal management of follicular cell thyroid cancer. We aimed to establish the distribution and frequency of common oncogenic gene mutations and chromosomal rearrangements in a comprehensive set of benign and malignant thyroid lesions. A case–control study was conducted in 413 surgical cases comprising 17 distinct histopathological categories, 244 malignant, 169 benign and 304 double-blinded specimens. Seventeen alterations of BRAF, HRAS, KRAS, NRAS, PAX8 and RET genes were evaluated using a single validated technology platform. Following verification of analytical sensitivity, accuracy and precision in model and surgical specimens, 152 molecular positive results were generated in lesions representing multiple stages of progression and epithelial differentiation as well as rare subtypes of primary, secondary or recurring tumors. Single mutations were found in 58% of primary malignant lesions and 12% of benign (p<0.001). In the blinded validation set, mutation distribution and frequency were distinct across variants of follicular and papillary carcinomas. BRAF or RET-PTC were detected exclusively in malignant lesions but not in follicular carcinomas (p<0.001). RAS or PAX8-PPARG were present in 23% of adenomas and NRAS was found in a single non-neoplastic lesion (p=0.0014). These data substantiate the diagnostic utility of molecular testing for oncogenic mutations and validate its performance in a variety of surgical specimens. Standardized and validated multi-analyte molecular panels can complement the pre- and postoperative assessment of thyroid nodules and support a growing number of clinical and translational applications with potential diagnostic, prognostic or theranostic utility.
    Human pathology 07/2014; 45(7). DOI:10.1016/j.humpath.2014.03.010 · 2.81 Impact Factor